1,412 companies

CompanyLast Price7D Return1Y ReturnMarket CapAnalysts TargetValuationGrowthDiv Yield

SH00

Shionogi
JP¥10.300%-1.0%JP¥1.8tJP¥35.08PE12.2xE0.4%7.9%

RPD

Royalty Pharma
US$24.420%n/aUS$12.6bUS$38.74PE18.8xE11.4%3.0%

EXK

Exact Sciences
US$60.45-4.2%-8.3%US$12.6bUS$71.09PS4.7xE70.9%n/a

ICY

Incyte
US$58.16-2.4%5.2%US$12.5bUS$65.53PE130.3xE41.1%n/a

IM8N

Insmed
US$64.50-3.7%166.5%US$12.5bUS$77.87PS37.9xE53.7%n/a

TE1

Bio-Techne
US$70.000%9.4%US$12.5bUS$73.89PE74.3xE18.3%0.4%

IM8N

Insmed
US$68.500%n/aUS$12.5bUS$82.70PS37.9xE53.7%n/a

ESF0

Eurofins Scientific
€58.005.0%7.4%€11.1b€60.44PE34xE18.4%0.9%

ESF0

Eurofins Scientific
€58.0011.9%7.4%€11.1b€60.44PE34xE18.4%0.9%

AB3A

Sarepta Therapeutics
US$110.95-2.0%-4.9%US$11.9bUS$173.17PE251.1xE44.1%n/a

NB3

Neurocrine Biosciences
US$103.30-2.5%-4.5%US$11.7bUS$151.47PE34.3xE29.3%n/a

RER1

Recordati Industria Chimica e Farmaceutica
€50.501.3%13.7%€10.4b€53.23PE26.8xE10.8%2.4%

B6E0

Swedish Orphan Biovitrum
SEK 13.800.7%50.0%SEK 112.3bSEK 13.77PE52.3xE25.9%n/a

B6E

Swedish Orphan Biovitrum
SEK 28.823.4%48.8%SEK 112.3bSEK 28.76PE52.3xE25.9%n/a

EII

Eisai
JP¥33.20-7.5%-36.8%JP¥1.6tJP¥44.82PE47.9xE16.2%2.9%

0C8

Catalent
US$53.680.5%25.1%US$10.9bUS$56.44PS2.5xE98.4%n/a

G2AB

Vifor Pharma
US$30.600.7%4.8%US$10.8bn/aPE15.9xS8.7%n/a

BKD

Bruker
US$62.683.3%6.2%US$10.7bUS$70.68PE30.4xE20.8%0.3%

I7G0

Ipsen
€27.20-0.7%-6.8%€9.2b€31.03PE13.9xE7.0%1.1%

I7G

Ipsen
€110.700%-9.4%€9.2b€126.27PE13.9xE7.0%1.1%

01P

Medpace Holdings
US$296.40-9.8%29.7%US$10.3bUS$348.30PE30.2xE13.5%n/a

RV6

Charles River Laboratories International
US$177.00-5.4%-3.9%US$10.2bUS$199.94PE23.7xE12.7%n/a

QIA

Qiagen
US$40.62-0.2%3.4%US$10.0bUS$45.76PE138.3xE37.1%n/a

QIA

Qiagen
US$41.022.3%4.0%US$10.0bUS$46.21PE138.3xE37.1%n/a
Page 6 of 59
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.